ES2157344T3 - Pirrolo(2,3-d)pirimidinas y su uso. - Google Patents

Pirrolo(2,3-d)pirimidinas y su uso.

Info

Publication number
ES2157344T3
ES2157344T3 ES95932693T ES95932693T ES2157344T3 ES 2157344 T3 ES2157344 T3 ES 2157344T3 ES 95932693 T ES95932693 T ES 95932693T ES 95932693 T ES95932693 T ES 95932693T ES 2157344 T3 ES2157344 T3 ES 2157344T3
Authority
ES
Spain
Prior art keywords
pyrimidins
sub
pirrolo
src
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932693T
Other languages
English (en)
Inventor
Martin Missbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2157344T3 publication Critical patent/ES2157344T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

SE PRESENTAN [2,3-D]PIRIMIDINAS DE FORMULA (I), EN DONDE R{SUB,1}, R{SUB,2} Y R{SUB,3}, SON TAL Y COMO SE LOS DEFINE EN LA DESCRIPCION. DICHOS COMPUESTOS TIENEN PROPIEDADES FARMACEUTICAS UTILES, Y SON ESPECIALMENTE EFECTIVOS COMO INHIBIDORES DE LA PROTEINA TIROSINA QUINASA PP60{SUP,C-SRC}. SU FORMA DE PREPARACION ES CONOCIDA PER SE.
ES95932693T 1994-09-29 1995-09-08 Pirrolo(2,3-d)pirimidinas y su uso. Expired - Lifetime ES2157344T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH295394 1994-09-29

Publications (1)

Publication Number Publication Date
ES2157344T3 true ES2157344T3 (es) 2001-08-16

Family

ID=4245363

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932693T Expired - Lifetime ES2157344T3 (es) 1994-09-29 1995-09-08 Pirrolo(2,3-d)pirimidinas y su uso.

Country Status (20)

Country Link
US (1) US5869485A (es)
EP (1) EP0783505B1 (es)
JP (1) JP4145955B2 (es)
KR (1) KR970706288A (es)
CN (1) CN1046731C (es)
AT (1) ATE199553T1 (es)
AU (1) AU694801B2 (es)
BR (1) BR9509048A (es)
CA (1) CA2200210A1 (es)
DE (1) DE69520282T2 (es)
DK (1) DK0783505T3 (es)
ES (1) ES2157344T3 (es)
FI (1) FI112867B (es)
GR (1) GR3035996T3 (es)
HU (1) HU222181B1 (es)
MX (1) MX9702307A (es)
NO (1) NO308108B1 (es)
NZ (1) NZ293249A (es)
PT (1) PT783505E (es)
WO (1) WO1996010028A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0836605B1 (en) * 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
CA2260999C (en) * 1996-07-19 2006-07-11 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use in tyrosine kinase inhibition
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
ES2239779T3 (es) 1996-10-02 2005-10-01 Novartis Ag Derivados de pirimidina y procedimientos para la preparacion de los mismos.
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL133430A0 (en) * 1997-08-05 2001-04-30 Pfizer Prod Inc 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
IL139787A0 (en) * 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
HK1039326A1 (zh) * 1998-09-18 2002-04-19 Abbott Gmbh & Co. Kg 4氨基吡咯并嘧啶作为激酶抑制剂
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
TW200801008A (en) * 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
US7659274B2 (en) * 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
JP2011515410A (ja) * 2008-03-19 2011-05-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 塩の形のｍＴＯＲ阻害剤
CA2740885C (en) * 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EP2861302A4 (en) 2012-05-14 2016-08-24 Prostagene Llc USE OF CCR5 MODULATORS FOR THE TREATMENT OF CANCER
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
US10550124B2 (en) * 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
JP2022553376A (ja) * 2019-10-25 2022-12-22 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung

Also Published As

Publication number Publication date
NZ293249A (en) 1999-04-29
BR9509048A (pt) 1998-01-06
CN1164234A (zh) 1997-11-05
HU222181B1 (hu) 2003-04-28
DE69520282T2 (de) 2001-08-09
DE69520282D1 (de) 2001-04-12
CA2200210A1 (en) 1996-04-04
FI971225L (fi) 1997-05-14
JP4145955B2 (ja) 2008-09-03
DK0783505T3 (da) 2001-07-02
JPH10506624A (ja) 1998-06-30
PT783505E (pt) 2001-08-30
HUT76785A (en) 1997-11-28
FI112867B (fi) 2004-01-30
GR3035996T3 (en) 2001-09-28
ATE199553T1 (de) 2001-03-15
KR970706288A (ko) 1997-11-03
AU3564395A (en) 1996-04-19
FI971225A0 (fi) 1997-03-24
CN1046731C (zh) 1999-11-24
WO1996010028A1 (en) 1996-04-04
AU694801B2 (en) 1998-07-30
EP0783505A1 (en) 1997-07-16
MX9702307A (es) 1998-04-30
NO971342L (no) 1997-03-21
US5869485A (en) 1999-02-09
EP0783505B1 (en) 2001-03-07
NO971342D0 (no) 1997-03-21
NO308108B1 (no) 2000-07-24

Similar Documents

Publication Publication Date Title
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
SE9504661D0 (sv) New compounds
NO980126D0 (no) Plaster-formulering for perkantal administrering av fenantyl
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
FI944729L (fi) Perhydroisoindolijohdannaiset substanssi P:n antagonisteina
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
IT1269826B (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
FR2686084B1 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
LV12260A (lv) Piridazino [4,5-b]-hinolina-5-oksida atvasinajumi to iegusana un to izmantosana par glicina antagonistiem
BR9711586A (pt) Compostos e uso dos mesmo
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
IT1174474B (it) Procedimento per la preparazione di formulazione galeniche particolarmente per uso farmaceutico, dietetico, cosmetico e diagnostico
FR2769915B1 (fr) Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
DE69033745D1 (de) Oberflächenaktive zusammensetzungen und verfahren
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
ITMI950098A0 (it) Procedimento per la preparazione di composti metallocenici
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FR2771093B1 (fr) Derives d'imidazole, leur preparation et leur application en therapeutique
SE9504662D0 (sv) New compounds
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783505

Country of ref document: ES